Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Huigene Therapeutics Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active case is assigned to 1 distinct examiner and 1 distinct art unit. The company's current prosecution activity is focused on a single point of contact within the patent office, reflecting a specialized approach to their pharmaceutical filings.
LOUNTOS, GEORGE THEMISTOCLIS is the busiest examiner for the company, holding 1 pending office action. This busiest examiner pending count of 1 represents the entirety of the company's current pending workload. This data highlights a concentrated effort within a single art unit for the company's current pharmaceutical filings. For practitioners, this indicates that the outcome of the company's current pipeline is entirely dependent on the examination style of LOUNTOS, GEORGE THEMISTOCLIS.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 57.1% | +60.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17836175 | ENGINEERED CRISPR/CAS13 SYSTEM AND USES THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17836175 | ENGINEERED CRISPR/CAS13 SYSTEM AND USES THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17836175 | ENGINEERED CRISPR/CAS13 SYSTEM AND USES THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102§112 | Final Rejection | — | Pending | Jun 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHuigene Therapeutics Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
George Themistoclis Lountos has the most, with 1 of Huigene Therapeutics Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
